PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
10 mai 2023 08h00 HE
|
PMV Pharmaceuticals, Inc.
Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation;...
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
01 mars 2023 08h00 HE
|
PMV Pharmaceuticals, Inc.
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV...
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March
28 févr. 2023 16h05 HE
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
22 nov. 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
08 nov. 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation ...
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
04 nov. 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
09 août 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y220C...
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
18 juil. 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
08 juin 2022 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
07 juin 2022 12h00 HE
|
PMV Pharmaceuticals, Inc.
Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1 Partial responses observed across six distinct tumor typesData featured as an oral presentation at ASCO;...